X

Jagsonpal Pharmaceuticals Ltd. Stock Analysis

Small Cap
Evaluated by 332 users | BSE: 507789 | NSE: JAGSNPHARM |
Pharmaceuticals & Drugs
In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed 10.82%8.29%8.25%4.09%4.42%3.19%5.13%3.74%-9.89%7.21%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 140161177166144138143144127167
Y-o-Y Gr. Rt.-15.3%9.7%-5.7%-13.6%-4%3.9%0.3%-12.1%31.9%
Adjusted EPS (Rs.) 3.532.742.850.70.810.451.241.11-4.412.75
Y-o-Y Gr. Rt.--22.4%4%-75.4%15.7%-44.4%175.6%-10.5%-497.3%NA
Book Value per Share (Rs.) 28.0930.2532.5232.6332.8633.4334.5538.9634.4336.89
Adjusted Net Profit 9.27.27.51.82.11.23.32.9-11.67.2
Net Op. Cash Flow (Rs. Cr.) 0.957.112.17.54.39-3.2-1.630.9
Debt to Cash Flow from Ops 23.715.754.932.774.789.154.26-2.45-5.270.12
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Jagsonpal Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 2%3%5.2%31.9%
Adjusted EPS -2.7%27.7%30.4%NA
Book Value per Share 3.12.32.27.1
Share Price 13.2% 4.4% 6.5% 46.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) 11.027.967.791.862.151.213.362.79-11.117.13
Operating Profit Margin (%) 11.269.039.416.047.426.328.234.01-8.785.6
Net Profit Margin (%) 6.624.464.221.11.470.852.272.02-9.134.33
Debt to Equity 0.280.360.410.390.420.450.430.080.090.04
Working Capital Days 161150159180209226227243277178
Cash Conversion Cycle 138126134148176186180190209110
Entity Percentage Holding
Promoters 70.34%
Non-Institutions 29.66%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Jagsonpal Pharma's performance infers:

Jagsonpal Pharma earnings have grown by 27.7%, whereas share price has appreciated 4.4% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Jagsonpal Pharma share prices over the last 10 years. Here is what we found out:

Jagsonpal Pharma share price has appreciated 4.1% annually over the past ten years.

In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.

In 1978, Fourteen years later,

In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.

In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the country’s leading pharmaceutical companies.

In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.

In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpal’s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpal’s current aggressive growth strategy.

Jagsonpal is among India’s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.

The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.

Product range of the company includes:

  • Dextropropoxyphene
  • Tolnaftate 
  • Indocap SR
  •  Sterile Unipacks 
  • Thiopental sodium

Upcoming products:

  • Nandralone laurate
  • Ethisterone
  • Norgestimate
  • Estradiol
  • Estradiol benzoate
  • Estradiol valerate
  • Estradiol phenylpropionate
  • Mifepristone
  • Finasteride/dutasteride
  • Budesonide
  • Cyproterone/acetate
  • Mestranol
  • Llynestrenol
  • Norethisterone enanthate
  • Estriol base and succinate
  • Ethinyl estradiol
  • Estrone
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback